Streetbeat News

Stock Prices

ABM

ABM Industries shares surged following the announcement of better-than-expected Q1 results and an upward revision of its FY24 EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 4:06 pm

HDSN

Hudson Technologies' shares dropped following the announcement of their Q4 financial results. Concurrently, B. Riley Securities reaffirmed a Buy rating on HDSN but reduced the price target from $17 to $16.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 4:03 pm

CECO

CECO Environmental Corp. shares have seen an increase in their trading value following the decision by multiple analysts to raise their price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 4:02 pm

REAX

The Real Brokerage Inc. shares experienced an increase following the announcement of their fourth-quarter revenue results, which surpassed expectations.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 4:01 pm

CCOI

Analyst ratings for Cogent Comms Hldgs (NASDAQ:CCOI) show a mix of sentiments, with recent adjustments including both raised and lowered price targets. The average 12-month price target is now $80.0, reflecting a slight decrease. Cogent, a significant player in internet traffic and broadband for businesses, has shown impressive financial performance with a revenue growth rate of 79.04% and a net margin of 73.56%. Despite this, its revenue growth rate is below the sector average.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 4:01 pm

DVN

Devon Energy (NYSE:DVN) has received mixed analyst ratings over the past quarter, with a total of 8 analysts offering opinions ranging from bullish to bearish. The average 12-month price target is $55.88, a decrease from the previous $58.00. Analyst actions include maintaining, lowering, and raising ratings and price targets, reflecting varied perceptions of the company's market position. Devon Energy, a major exploration and production company in North America, has shown a negative revenue trend with a -3.58% growth, a below-industry net margin, but impressive ROE and ROA figures. The company's debt-to-equity ratio is higher than the industry average.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 4:01 pm

ARHS

Arhaus shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company's forecast for FY24 net revenue is higher than analysts' estimates.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 4:01 pm

INVH

Invitation Homes (NYSE:INVH) has been evaluated by 7 analysts over the last three months, showing a mix of bullish to bearish sentiments. The recent ratings reveal a shift towards a more positive outlook, with an average 12-month price target of $38.43, up from $35.80. The company's financial performance indicates strong market position, revenue growth, and profitability, with a market capitalization surpassing industry averages and a net margin of 20.72%. Analysts' actions and price target adjustments reflect their response to the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 4:01 pm

CSCO

The analysis compares Cisco Systems (CSCO) with its competitors in the Communications Equipment industry, highlighting financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Cisco's lower P/E and P/B ratios suggest undervaluation, while its high P/S ratio may indicate overvaluation in sales performance. Despite a lower ROE, Cisco shows strong profitability, robust cash flow, and better revenue growth than the industry average. Cisco's lower debt-to-equity ratio suggests a stronger financial position with less reliance on debt.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 4:00 pm

BSX

17 analysts have provided mixed ratings for Boston Scientific (NYSE:BSX), with a recent shift towards more bullish perspectives. The average 12-month price target is now $69.24, marking a 10.78% increase from the previous target. Analysts have adjusted their ratings and price targets, reflecting optimism about the company's performance. Boston Scientific, known for its less invasive medical devices, has shown a positive revenue trend with a 14.9% growth rate as of December 31, 2023, but faces challenges in ROE and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 4:00 pm